Devel. and Eval. of an Active Surveillance Decision Aid for Men With Low or Intermediate Grade Prostate Cancer

University of Rochester140 enrolled

Overview

The overall goal of this project is to test an interactive, multi-media decision aid in the form of an electronic clinical decision dashboard designed to improve the quality of clinical decision making for initial treatment of patients with newly diagnosed, low or intermediate risk prostate cancer. Specifically, we propose to conduct a clinical trial to compare the effects of a prostate decision dashboard versus usual care on: 1. patient knowledge regarding the treatment options available for low or intermediate risk prostate cancer, 2. measures of the decision making process including decisional conflict and the extent to which decisions were made via a shared decision making process, 3. the treatments selected, and 4. 3-6 and 9-12 month outcome assessments of clinical status, decision regret, cancer-related quality of life including worry, functional status, and treatment side effects.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

SUPPORTIVE_CARE

Masking

NONE

Enrollment

140

Conditions

Adenocarcinoma of Prostate

Interventions

DashboardBEHAVIORAL

With the health care provider, subjects will use the decision dashboard to augment the discussion of treatment options.

Eligibility

Sex: MALEMin age: 40 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age: 40 to 85 years * Sex: male * Race/ethnicity: no restrictions * Diagnosis: Patients will be eligible for the study if they have not yet decided on a management plan and present with either: * localized, low grade prostate cancer, defined as Gleason score ≤ 6, T1-T2a stage cancers, and PSA values \< 10 ng/ml, OR * Intermediate risk prostate cancer, defined as Gleason score = 7, T2b-T2c stage cancers (these tumors involve more of the prostate but do not extend beyond the prostatic capsule), or PSA 10-20 ng/ml * Willing to participate and able to give informed consent * Able to adequately see the study intervention which is an interactive decision dashboard \& complete study-related questionnaires * Able to understand English language adequately to use the decision dashboard and complete study-related questionnaires Exclusion Criteria: * Unable to complete study-related tasks due to cognitive deficits or English non-fluency * Unwilling to participate. * Deemed clinically unsuitable for active surveillance as a prostate cancer management option

Locations (1)

University of Rochester Medical Center

Rochester, New York, United States

Outcomes

Primary Outcomes

Increase in KUJ score through education

The use of the dashboard will increase patient knowledge and understanding of treatment options as measured using KUJ questionnaire.

Time frame: 2 years

Secondary Outcomes

Measure of overall quality and satisfaction with initial treatment decision.

The use of the dashboard will improve the overall quality and satisfaction with initial treatment decisions as measured by a) decisional conflict, b) patient quality of life, and c) post-decision regret, using the PORPUS questionnaire and Decisional Regret questionnaire.

Time frame: 2 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.